Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes

Drug Metabolism and Disposition

Volumn 28, Issue 8, 2000, Pages 966-972

  Abelo, A ^a   Andersson, T B ^a   Antonsson, M ^a   Naudot, A K ^a   Skanberg, I ^a   Weidolf, L ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; ISOMER; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOCHEMISTRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; STEREOISOMERISM;

EID: 0033856082     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole
2. Pharmacokinetics, metabolism and interactions of acid pump inhibitors - Focus on omeprazole, lansoprazole and pantoprazole
3. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (AOP) of omeprazole and its 2 optical isomers, S- omeprazole/esomeprazole (E) and R-omeprazole (R-O)
4. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
5. High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism
6. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism
7. Enantioselective high-performance liquid chromatographic determination of omeprazole in human plasma
8. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4-hydroxylation
9. Enzyme-structure relationships in the endoplasmic reticulum of rat liver
10. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
11. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
12. Utility of in vitro drug metabolism data in predicting in vivo metabolism
13. Identification of residues 99, 220 and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity
14. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
15. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes
16. Determination of R(+)- and S(-)-lansoprazole using chiral stationary- phase liquid chromatography and their enantioselective pharmacokinetics in humans
17. Molecular modeling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: Rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily
18. Molecular modeling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes
19. Protein measurement with the folin phenol reagent
20. Identification of the human P450 enzymes involved in lansoprazole metabolism
21. Pharmacokinetics and metabolism of omeprazole in animals and man - An overview
22. Pantoprazole - Which cytochrome P450 isoenzymes are involved in its biotransformation
23. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of pantoprazole - A preliminary study
24. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
25. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor
26. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples